HK1167082A1 - 治療局部缺血和缺血-再灌注損傷的組合物與方法 - Google Patents

治療局部缺血和缺血-再灌注損傷的組合物與方法

Info

Publication number
HK1167082A1
HK1167082A1 HK12107721.7A HK12107721A HK1167082A1 HK 1167082 A1 HK1167082 A1 HK 1167082A1 HK 12107721 A HK12107721 A HK 12107721A HK 1167082 A1 HK1167082 A1 HK 1167082A1
Authority
HK
Hong Kong
Prior art keywords
ischemia
compositions
methods
reperfusion injury
treating
Prior art date
Application number
HK12107721.7A
Other languages
English (en)
Inventor
Alexander B Baguisi
Reinier Beeuwkes
Ralph Casale
Steven A Kates
Alan S Lader
Original Assignee
Ischemix Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ischemix Llc filed Critical Ischemix Llc
Publication of HK1167082A1 publication Critical patent/HK1167082A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
HK12107721.7A 2009-05-14 2012-08-06 治療局部缺血和缺血-再灌注損傷的組合物與方法 HK1167082A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/466,170 US7928067B2 (en) 2009-05-14 2009-05-14 Compositions and methods for treating ischemia and ischemia-reperfusion injury
PCT/US2010/034701 WO2010132657A1 (en) 2009-05-14 2010-05-13 Compositions and methods for treating ischemia and ischemia-reperfusion injury

Publications (1)

Publication Number Publication Date
HK1167082A1 true HK1167082A1 (zh) 2012-11-23

Family

ID=42244916

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12107721.7A HK1167082A1 (zh) 2009-05-14 2012-08-06 治療局部缺血和缺血-再灌注損傷的組合物與方法

Country Status (17)

Country Link
US (5) US7928067B2 (zh)
EP (1) EP2429519B1 (zh)
JP (2) JP5570590B2 (zh)
KR (1) KR101636395B1 (zh)
CN (1) CN102802622B (zh)
AU (1) AU2010249001B2 (zh)
BR (1) BRPI1012182A2 (zh)
CA (1) CA2761798C (zh)
DK (1) DK2429519T3 (zh)
ES (1) ES2470673T3 (zh)
HK (1) HK1167082A1 (zh)
IL (2) IL216349A (zh)
MX (2) MX347460B (zh)
NZ (1) NZ596364A (zh)
PL (1) PL2429519T3 (zh)
SG (1) SG176062A1 (zh)
WO (1) WO2010132657A1 (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541396B2 (en) 2009-04-24 2013-09-24 National University Of Singapore Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agent
US7928067B2 (en) * 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
JP2014502264A (ja) * 2010-11-18 2014-01-30 イスケミックス エルエルシー リポイル化合物および虚血性傷害を治療するためのその使用
EP2540292A1 (en) * 2011-06-28 2013-01-02 Nestec S.A. DHA and EPA in the reduction of oxidative stress
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
KR102578891B1 (ko) 2012-05-11 2023-09-15 주식회사 젬백스앤카엘 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
US9844584B2 (en) 2012-05-11 2017-12-19 Gemvax & Kael Co., Ltd. Composition for preventing or treating sepsis
EP2873678B1 (en) 2012-07-11 2024-06-26 Gemvax & Kael Co.,Ltd Conjugate comprising a cell-penetrating peptide and compositions comprising same
WO2014171792A1 (ko) * 2013-04-19 2014-10-23 주식회사 카엘젬백스 허혈성 손상 치료 및 예방용 조성물
CA2912557A1 (en) 2013-06-07 2014-12-11 Gemvax & Kael Co., Ltd. Biological markers useful in cancer immunotherapy
ES2808076T3 (es) 2013-06-21 2021-02-25 Gemvax & Kael Co Ltd Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso
EP3061459B1 (en) 2013-10-23 2019-12-11 Gemvax & Kael Co., Ltd. Composition for treating and preventing benign prostatic hyperplasia
WO2015076621A1 (ko) 2013-11-22 2015-05-28 주식회사 카엘젬백스 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
EP3085380B1 (en) 2013-12-17 2020-06-17 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
WO2015156649A1 (ko) 2014-04-11 2015-10-15 주식회사 젬백스앤카엘 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
ES2962532T3 (es) 2014-04-30 2024-03-19 Gemvax & Kael Co Ltd Composición para el trasplante de órganos, tejidos o células, kit y procedimiento de trasplante
WO2015174948A1 (en) 2014-05-14 2015-11-19 Ischemix, LLC Formulations comprising lipoyl compounds
CN104095835A (zh) * 2014-06-20 2014-10-15 广州军区广州总医院 对羟基苄叉丙酮在制备预防和/或治疗肝缺血/再灌注损伤药物中的应用
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
ES2799511T3 (es) 2015-02-27 2020-12-18 Gemvax & Kael Co Ltd Péptido para prevenir la pérdida de audición, y composición que lo comprende
KR102638286B1 (ko) 2015-07-02 2024-02-20 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
CN117018162A (zh) 2016-04-07 2023-11-10 珍白斯凯尔有限公司 具有增加端粒酶活性和延长端粒的效果的肽以及组合物
CN106083800A (zh) * 2016-06-13 2016-11-09 崔坤峰 氯普噻吨的药物组合物及对脑缺血再灌注损伤的保护作用
KR20190062502A (ko) * 2016-10-05 2019-06-05 미토브리지, 인크. 급성 신장 손상을 치료하는 방법
JP7203756B2 (ja) 2017-04-25 2023-01-13 イスケミックス エルエルシー 外傷性脳傷害を治療するための組成物および方法
KR102112949B1 (ko) 2019-02-12 2020-05-19 남현규 복합 효모 발효로 불용 단백질을 가용화하여 화장품원료를 추출하는 화장품원료 제조방법

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1047991B (de) 1957-11-20 1958-12-31 Nordmark Werke Gmbh Verfahren zur Herstellung chemisch stabiler, untoxischer, steriler Injektionsloesungen von Thioctsaeure
US3875207A (en) * 1967-01-25 1975-04-01 Ciba Geigy Corp Process for the temporary protection of amino groups in peptide syntheses
CA1219824A (en) 1981-04-17 1987-03-31 David C. Ward Modified nucleotides and methods of preparing and using same
US5288706A (en) * 1987-12-25 1994-02-22 Mitsui Toatsu Chemicals, Incorporated Medicament for prevention and remedy of diseases of the pancreas and others
FR2653334B1 (fr) 1989-10-19 1991-12-20 Erphar Ste Civile Preparation cosmetique de bronzage.
DE4035442B4 (de) 1989-11-09 2010-04-29 Evonik Degussa Gmbh Arzneimittel enthaltend als Wirkstoff R-α-Liponsäure
DE4000397A1 (de) 1990-01-09 1991-07-11 Hoechst Ag Lipidselektive antioxidantien sowie deren herstellung und verwendung
DE69330386T2 (de) 1992-04-24 2002-05-16 Biocompatibles Ltd Verfahren zur verminderung von mikroorganismenhaftung
DE4235912C2 (de) 1992-10-23 2002-12-05 Viatris Gmbh Verfahren zur Herstellung kristalliner Thioctsäure und deren Verwendung
DE4433764A1 (de) 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
WO1997000889A1 (fr) * 1995-06-21 1997-01-09 Asahi Kasei Kogyo Kabushiki Kaisha Peptides de liaison de lipoproteines de faible densite
JPH0990542A (ja) 1995-09-28 1997-04-04 Konica Corp ハロゲン化銀写真感光材料
FR2741075B1 (fr) 1995-11-15 1998-01-30 Rech De Pathologie Appliquee S Conjugues peptidiques, leur utilisation a titre de medicament et compositions les contenant
AU728488B2 (en) 1997-04-02 2001-01-11 Sankyo Company Limited Dithiolan derivatives, their preparation and their therapeutic effect
JPH117099A (ja) 1997-06-13 1999-01-12 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US6090842A (en) 1998-03-10 2000-07-18 The Regents Of The University Of California Lipoic acid analogs
DE19834608A1 (de) 1998-07-31 2000-02-03 Basf Ag Kristallmodifikation der Liponsäure
JP2000169371A (ja) 1998-10-02 2000-06-20 Sankyo Co Ltd ジチオラン誘導体を含有する医薬
CA2352555A1 (en) 1998-11-26 2000-06-08 Pentapharm Ag Transport system conjugate
WO2001009118A2 (en) 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
US6890896B1 (en) 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
JP2003518477A (ja) * 1999-11-18 2003-06-10 セレメディックス，インク． 反応性酸素種およびフリーラジカルの効力を中和するための組成物および方法
US6664287B2 (en) 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
US8795706B2 (en) 2000-08-16 2014-08-05 Encore Health, Llc Methods of treating ocular diseases using derivatives of lipoic acid
JP2002189271A (ja) 2000-12-21 2002-07-05 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料およびその処理方法
JP4072062B2 (ja) 2001-03-19 2008-04-02 千寿製薬株式会社 新規α−リポ酸誘導体およびその用途
EP1521735A2 (en) 2001-05-25 2005-04-13 Ceremedix, Inc Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
JP4259813B2 (ja) 2001-05-29 2009-04-30 千寿製薬株式会社 α−リポイルアミノ酸の安定化法および安定化されたα−リポイルアミノ酸を含有する水性液剤
DE10163836A1 (de) 2001-12-22 2003-07-10 Friz Biochem Gmbh Multifunktionales Reagenz zur Synthese von thiolmodifizierten Oligomeren
JP4272068B2 (ja) 2001-12-26 2009-06-03 日本曹達株式会社 自己組織化単分子膜を形成する電子受容性化合物
AUPS065102A0 (en) 2002-02-20 2002-03-14 Unisearch Limited Fluorous acetalation
EP1476440A4 (en) 2002-02-22 2005-06-01 Albany College Of Pharmacy METHODS AND COMPOUNDS USEFUL IN INHIBITION BY RADICAL AND / OR OXIDIZING AGGRESSION AND IN THE TREATMENT AND PREVENTION OF DISEASE
JP2003286168A (ja) 2002-03-28 2003-10-07 Senju Pharmaceut Co Ltd α−リポイルアミノ酸を含有する皮膚外用剤
JP4376540B2 (ja) 2002-05-31 2009-12-02 アイバイツ株式会社 金属表面修飾剤および新規含硫黄化合物
US7030154B2 (en) 2002-06-07 2006-04-18 Juvenon, Inc. Stability of lipoic acid
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
EP1454627A1 (en) 2003-03-06 2004-09-08 MyoContract Ltd. Alpha-Keto carbonyl calpain inhibitors
US20040204340A1 (en) * 2003-04-11 2004-10-14 Guilford Pharmaceuticals, Inc. Polyprolyl inhibitors of cyclophilin
US7202270B2 (en) 2003-06-20 2007-04-10 Sami Labs Limited Convenient stable non-hygroscopic crystalline solid forms of racemic and chiral LA-plus salts: process for their manufacture and uses
WO2005063732A1 (en) 2003-12-23 2005-07-14 Microbia, Inc. Compounds and methods for the treatment of asthma
EP1726596A4 (en) 2004-02-18 2009-08-26 Japan Science & Tech Agency SUGAR CHAIN LIGAND COMPOSITE AND METHOD OF PROTEIN ANALYSIS WITH LIGAND COMPOSITE
JP2006022066A (ja) 2004-07-09 2006-01-26 Shiseido Co Ltd 重合抑制剤および即時型黒化防止用皮膚外用剤
WO2006101909A2 (en) 2005-03-16 2006-09-28 Ischemix, Inc. Combination therapy for treating or preventing diseases
WO2006101910A2 (en) 2005-03-16 2006-09-28 Ischemix, Inc. Peptide compounds and methods of using peptide compounds to treat conditions affecting the cardiac, pulmonary, and nervous systems
JP2008174453A (ja) 2005-04-28 2008-07-31 Iwaki Kk 頭皮脱毛治療剤
US8507439B2 (en) * 2005-08-29 2013-08-13 Angela Shashoua Neuroprotective and neurorestorative method and compositions
JP4951226B2 (ja) 2005-09-08 2012-06-13 立山化成株式会社 α−リポ酸アルカリ塩の製法
JP2009507848A (ja) * 2005-09-09 2009-02-26 オレゴン ヘルス アンド サイエンス ユニバーシティ 神経保護薬
ES2344920T3 (es) 2006-03-28 2010-09-09 Epitech Group S.R.L. Composicion farmaceutica para el tratamiento de patologias provocadas por la respuesta general del sistema inmutario.
WO2010052310A1 (en) 2008-11-07 2010-05-14 Segix Italia S.R.L. Alpha-lipoic acid derivatives and their use in drug preparation
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
US8080674B2 (en) 2009-06-12 2011-12-20 Ampac Fine Chemicals Llc. Preparation of polymer-free R-(+)-α-lipoic acid magnesium salt
WO2010147962A1 (en) 2009-06-15 2010-12-23 Encore Health, Llc Choline esters
IT1397154B1 (it) 2010-01-04 2013-01-04 Ghelardini Composti ad efficacia sia analgesica che antiperalgesica.
JP2014502264A (ja) 2010-11-18 2014-01-30 イスケミックス エルエルシー リポイル化合物および虚血性傷害を治療するためのその使用
US20150329519A1 (en) 2014-05-14 2015-11-19 Ischemix, LLC Formulations Comprising Lipoyl Compounds
WO2015174948A1 (en) 2014-05-14 2015-11-19 Ischemix, LLC Formulations comprising lipoyl compounds

Also Published As

Publication number Publication date
DK2429519T3 (da) 2014-05-19
MX2011012095A (es) 2012-03-26
JP2012526842A (ja) 2012-11-01
AU2010249001B2 (en) 2013-06-20
WO2010132657A1 (en) 2010-11-18
EP2429519A1 (en) 2012-03-21
CA2761798C (en) 2018-08-07
US20110160294A1 (en) 2011-06-30
JP2014077003A (ja) 2014-05-01
US20140274917A1 (en) 2014-09-18
US8772250B2 (en) 2014-07-08
IL216349A0 (en) 2012-01-31
US20120135932A1 (en) 2012-05-31
CN102802622B (zh) 2017-03-15
EP2429519B1 (en) 2014-04-23
ES2470673T3 (es) 2014-06-24
US20160264622A1 (en) 2016-09-15
US8772249B2 (en) 2014-07-08
KR20120018188A (ko) 2012-02-29
US9540417B2 (en) 2017-01-10
PL2429519T3 (pl) 2014-09-30
NZ596364A (en) 2013-07-26
AU2010249001A1 (en) 2011-12-01
IL216349A (en) 2015-11-30
BRPI1012182A2 (pt) 2016-04-05
US20100292313A1 (en) 2010-11-18
JP5570590B2 (ja) 2014-08-13
CA2761798A1 (en) 2010-11-18
IL237820A (en) 2016-12-29
CN102802622A (zh) 2012-11-28
US7928067B2 (en) 2011-04-19
JP5767307B2 (ja) 2015-08-19
SG176062A1 (en) 2011-12-29
MX347460B (es) 2017-04-26
KR101636395B1 (ko) 2016-07-05

Similar Documents

Publication Publication Date Title
HK1167082A1 (zh) 治療局部缺血和缺血-再灌注損傷的組合物與方法
IL239918A0 (en) Preparations for the treatment of colitis
IL218987A0 (en) Methods and compositions for treating cancer
EP2396019A4 (en) METHOD AND COMPOSITIONS FOR SKIN TREATMENT
IL214664A (en) Compositions are useful for treating hair-related conditions
EP2504428A4 (en) METHOD AND COMPOSITIONS FOR TREATING OXALATE-MEDIATED SUFFERING
IL210097A0 (en) Compositions and methods for treating unfluenza
EP2419136A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP2429584A4 (en) TREATMENT PROCEDURE AND COMPOSITIONS
EP2544655A4 (en) COMPOSITIONS AND METHODS FOR TREATING SKIN
HK1161082A1 (zh) 用於治療再灌注損傷的方法
IL215932A0 (en) Compositions and methods for treating burns
ZA201202561B (en) Compositions and methods for enhancing cognitive and related functions in animals
IL216146A0 (en) Methods and compositions for treating lupus
IL277220A (en) Neurogulin preparations for use in the treatment of peripheral nerve injury
HK1244706A1 (zh) 用於治療勃起功能障礙的組成物及方法
EP2485738A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF ADIPOSITAS
EP2340254A4 (en) COMPOSITIONS AND METHODS FOR TREATING EPILEPSY
EP2384115A4 (en) METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANT TUMORS
PT2621517E (pt) Composição para uso no tratamento da infertilidade
EP2473506A4 (en) COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER
HK1167350A1 (zh) 保護和治療神經損傷的方法和組合物
EP2393506A4 (en) METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES
EP2427052A4 (en) METHODS AND COMPOSITIONS FOR USE IN THE TREATMENT OF OPHTHALMIC DISORDERS
IL217764A0 (en) Methods and compositions for treating leukemia